UA105042C2 - Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання - Google Patents
Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержанняInfo
- Publication number
- UA105042C2 UA105042C2 UAA201113932A UAA201113932A UA105042C2 UA 105042 C2 UA105042 C2 UA 105042C2 UA A201113932 A UAA201113932 A UA A201113932A UA A201113932 A UAA201113932 A UA A201113932A UA 105042 C2 UA105042 C2 UA 105042C2
- Authority
- UA
- Ukraine
- Prior art keywords
- preparation
- pharmaceutical composition
- oral pharmaceutical
- hydrophilic drug
- hydrophilic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Описано самомікроемульговувану оральну фармацевтичну композицію гідрофільного лікарського засобу чи його фармацевтично придатної солі та спосіб їх одержання. Композиція містить гідрофільний лікарський засіб, наприклад бендамустин чи гемцитабін, розчинник, поверхнево-активну речовину та гідрофільний носій, та має добру біодоступність та стабільність. Вказаний гідрофільний носій є сумісним з розчином лікарського засобу та поверхнево-активною речовиною.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17290109P | 2009-04-27 | 2009-04-27 | |
PCT/CN2010/000577 WO2010124525A1 (zh) | 2009-04-27 | 2010-04-27 | 亲水性药物之自微乳化医药组合物及其制备 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA105042C2 true UA105042C2 (uk) | 2014-04-10 |
Family
ID=42992661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201113932A UA105042C2 (uk) | 2009-04-27 | 2010-04-27 | Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання |
Country Status (21)
Country | Link |
---|---|
US (3) | US20100273730A1 (uk) |
EP (2) | EP3045165B1 (uk) |
JP (1) | JP5753157B2 (uk) |
KR (1) | KR101759750B1 (uk) |
CN (1) | CN102427803B (uk) |
AU (1) | AU2010242461B2 (uk) |
BR (1) | BRPI1011764A2 (uk) |
CA (1) | CA2760039C (uk) |
CO (1) | CO6470799A2 (uk) |
ES (1) | ES2831037T3 (uk) |
HK (1) | HK1165701A1 (uk) |
IL (1) | IL215988A (uk) |
MX (1) | MX349014B (uk) |
MY (1) | MY174001A (uk) |
NZ (1) | NZ596657A (uk) |
RU (1) | RU2532362C2 (uk) |
SG (1) | SG175808A1 (uk) |
TW (1) | TWI461212B (uk) |
UA (1) | UA105042C2 (uk) |
WO (1) | WO2010124525A1 (uk) |
ZA (1) | ZA201108686B (uk) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3158991B1 (en) | 2010-01-28 | 2021-03-17 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
ES2690257T3 (es) * | 2010-06-02 | 2018-11-20 | Astellas Deutschland Gmbh | Formas de dosificación oral de bendamustina |
JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
DK2827862T3 (da) | 2012-03-20 | 2024-02-12 | Eagle Pharmaceuticals Inc | Formuleringer af bendamustin |
WO2013142359A1 (en) | 2012-03-20 | 2013-09-26 | Eagle Pharmaceuticals, Inc. | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2015031198A2 (en) | 2013-08-27 | 2015-03-05 | Voudouris Vasilios | Bendamustine pharmaceutical compositions |
IN2014CH00151A (uk) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation | |
MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
MX2017005883A (es) | 2014-11-04 | 2017-11-28 | Innopharmax Inc | Administracion oral de farmacos inestables o deficientemente absorbidos. |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10335405B1 (en) * | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
EP3463298B1 (en) * | 2016-06-02 | 2021-09-01 | Innopharmax, Inc. | Metronomic oral gemcitabine for cancer therapy |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
US20200206139A1 (en) * | 2017-09-11 | 2020-07-02 | Board Of Regents, The University Of Texas System | Compositions for the improved delivery of drugs |
CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
KR20220167271A (ko) * | 2020-04-13 | 2022-12-20 | 유에스 나노 푸드 앤 드럭 인코포레이티드 | 염기성 화학요법 종양내 주사 제형 |
CN112006986A (zh) * | 2020-08-07 | 2020-12-01 | 厦门大学 | 一种维生素e琥珀酸酯聚乙二醇纳米胶束及其制备方法和应用 |
CN114397381A (zh) * | 2021-12-17 | 2022-04-26 | 南京农业大学 | 一种沼液中阿莫西林的提取及含量检测方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
DE69434626D1 (de) * | 1993-11-17 | 2006-04-20 | Athena Neurosciences Inc | Transparente flüssigkeit zur verabreichung von verkapselten medikamenten |
CA2316539C (en) * | 1997-12-26 | 2008-11-18 | Yamanouchi Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US7217735B1 (en) * | 1999-04-09 | 2007-05-15 | Au Jessie L-S | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US7309696B2 (en) * | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
KR100915741B1 (ko) * | 2001-06-15 | 2009-09-04 | 코너스톤 파마슈티칼스 | 표적 조직 및 세포를 치료하기에 유용한 나노입자를함유하는 약제학적 및 진단학적 조성물 |
CA2455288A1 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
US7053076B2 (en) * | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
DE10306724A1 (de) * | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
DE60318035T2 (de) * | 2002-05-03 | 2008-12-11 | Janssen Pharmaceutica N.V. | Polymermikroemulsionen |
AU2003268087A1 (en) | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
CN1593405A (zh) | 2004-07-09 | 2005-03-16 | 沈阳药科大学 | 一种氟康唑液体型组方及其制剂 |
EP1674081A1 (de) * | 2004-12-23 | 2006-06-28 | KTB Tumorforschungsgesellschaft mbH | Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge |
CA2640598A1 (en) | 2006-02-03 | 2007-08-09 | Noboru Yamazaki | Liposome preparation |
US20070264349A1 (en) * | 2006-03-07 | 2007-11-15 | Novavax, Inc. | Nano-structured compositions and methods of making and using the same |
KR101545874B1 (ko) * | 2007-09-03 | 2015-08-20 | 나노테라퓨틱스, 인코포레이티드 | 난용성 약물의 전달을 위한 입상 조성물 |
-
2010
- 2010-04-26 US US12/767,293 patent/US20100273730A1/en not_active Abandoned
- 2010-04-27 WO PCT/CN2010/000577 patent/WO2010124525A1/zh active Application Filing
- 2010-04-27 EP EP16159341.3A patent/EP3045165B1/en active Active
- 2010-04-27 KR KR1020117028150A patent/KR101759750B1/ko active IP Right Grant
- 2010-04-27 CN CN201080018431.0A patent/CN102427803B/zh active Active
- 2010-04-27 RU RU2011148140/15A patent/RU2532362C2/ru active
- 2010-04-27 NZ NZ596657A patent/NZ596657A/en unknown
- 2010-04-27 UA UAA201113932A patent/UA105042C2/uk unknown
- 2010-04-27 ES ES16159341T patent/ES2831037T3/es active Active
- 2010-04-27 MY MYPI2011005198A patent/MY174001A/en unknown
- 2010-04-27 EP EP10769214A patent/EP2425818A4/en not_active Withdrawn
- 2010-04-27 SG SG2011078912A patent/SG175808A1/en unknown
- 2010-04-27 AU AU2010242461A patent/AU2010242461B2/en active Active
- 2010-04-27 MX MX2011011374A patent/MX349014B/es active IP Right Grant
- 2010-04-27 BR BRPI1011764A patent/BRPI1011764A2/pt not_active Application Discontinuation
- 2010-04-27 JP JP2012507575A patent/JP5753157B2/ja active Active
- 2010-04-27 CA CA2760039A patent/CA2760039C/en active Active
- 2010-04-27 TW TW099113339A patent/TWI461212B/zh active
-
2011
- 2011-10-27 IL IL215988A patent/IL215988A/en active IP Right Grant
- 2011-11-22 CO CO11159571A patent/CO6470799A2/es not_active Application Discontinuation
- 2011-11-25 ZA ZA2011/08686A patent/ZA201108686B/en unknown
-
2012
- 2012-06-25 HK HK12106178.7A patent/HK1165701A1/xx unknown
-
2015
- 2015-03-26 US US14/669,233 patent/US20150196537A1/en not_active Abandoned
-
2019
- 2019-05-23 US US16/420,581 patent/US20190275006A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA105042C2 (uk) | Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання | |
MY183312A (en) | Pharmaceutical formulation | |
AU2012259422A8 (en) | Solid forms of a pharmaceutically active substance | |
TN2013000253A1 (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
WO2011042918A3 (en) | Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof | |
MX2009011165A (es) | Formulaciones farmaceuticas que contienen derivados del acido lipoico. | |
WO2009006590A3 (en) | Docetaxel process and polymorphs | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
MY151986A (en) | Adamantyl diamide derivatives and uses of same | |
BRPI0910758A2 (pt) | composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
WO2011157722A3 (en) | Solid ivabradine-containing composition | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
WO2012140596A8 (en) | Glycoside derivatives and uses thereof | |
TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
BR112013013903A2 (pt) | preparação farmacêutica aquosa estável pronta para uso de cetrorelix para administração parenteral, processo para a fabricação de uma preparação farmacêutica aquosa estável pronta para uso de cetrorelix para uso de cetrorelix para administração parenteral | |
MX2012007393A (es) | Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam. | |
WO2012108631A3 (en) | Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof | |
WO2013062332A3 (ko) | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 | |
MX2012005596A (es) | Derivados de difenil azepano como inhibidores de reabsorcion de monoaminas. | |
AP2010005204A0 (en) | New addition salts of angiotensinconverting enzymeir preparation and pharmaceutical compositions coninhibitors with no donor acids, a process for the taining them | |
WO2013124832A3 (en) | Stabilized controlled-release pharmaceutical composition comprising gliclazide |